샘플 요청 목록

 카트 문의
시장보고서
상품코드
1726215

전립선암 바이오마커 시장 규모, 점유율, 동향 분석 보고서 : 유형별, 용도별, 최종 용도별, 지역별, 부문별 예측(2025-2030년)

Prostate Cancer Biomarkers Market Size, Share & Trends Analysis Report By Type (Genetic Biomarkers, Cell-based Biomarkers, Metabolomic Biomarkers), By Application, By End-use, By Region, And Segment Forecasts, 2025 - 2030
발행일: | 리서치사: Grand View Research | 페이지 정보: 영문 120 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    




※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

전립선암 바이오마커 시장의 성장과 동향

Grand View Research, Inc.의 최신 보고서에 따르면 세계 전립선암 바이오마커 시장 규모는 2025-2030년에 걸쳐 13.1%의 연평균 복합 성장률(CAGR)로 성장할 것으로 예상되며, 2030년까지 98억 달러에 이를 전망입니다.

이 시장은 정밀 진단에 대한 수요 증가와 PSA 검사와 같은 전통적인 스크리닝 방법의 한계에 따라 급속한 진화를 이루고 있습니다. PSA 검사는 널리 사용되지만 특이도가 낮으며 종종 과다 진단 및 과다 치료로 이어집니다. 그 결과, 진단 정밀도의 향상과 임상 판단의 지침이 되는 분자 바이오마커나 유전체 바이오마커로의 변화가 현저해지고 있습니다. PCA3(Prostate Cancer Antigen 3), 4Kscore, ConfirmMDx와 같은 새로운 바이오마커는 위험 계층화 및 생검 의사결정 지원에 탁월한 성능을 보여줍니다. 이러한 검사는 불필요한 생검을 줄이고 환자의 결과를 개선하기 위해 임상 진료에 점점 더 많이 통합되어 왔습니다.

주요 시장 성장 촉진요인은 맞춤형 의료에 대한 관심 증가입니다. Decipher GPS 및 Oncotype DX GPS와 같은 유전체 분류법은 전립선 종양의 악성도를 결정하고 치료 계획에 정보를 제공하는 데 도움이 됩니다. 리퀴드 바이옵시에 의한 기술도 그 비침습성으로부터 주목을 받고 있으며, SelectMDx나 ExoDx와 같은 소변 기반 검사는 PSA 상승 환자에 대한 임상적으로 실용적인 통찰을 기재하고 있습니다. 이러한 혁신은 전통적인 생검에 위험이 있거나 결론을 내리지 않는 경우 특히 관련성이 높습니다.

차세대 시퀀서(NGS)와 전사체학의 기술적 진보는 바이오마커 발견을 더욱 가속화하고 있습니다. 대조군 환자의 선택에서 이러한 바이오마커의 사용이 증가하는 것은 치료 생태계에서 동반진단의 중요성 증가를 반영합니다.

그러나 시장은 여전히 몇 가지 과제에 직면하고 있습니다. 바이오 마커 분석 간의 표준화는 여전히 제한적이며, 어떤 검사를 어떤 임상 단계에서 채용해야하는지에 대한 임상 의사들 사이에서 컨센서스가 얻어지지 않았습니다. 자동차 검사의 일상적인 사용을 방해할 수 있습니다. 또한, 바이오마커 승인을 위한 규제상의 경로는 종종 장기간에 걸쳐, 시판이 지연될 가능성이 있습니다.

이러한 장벽에도 불구하고, 전립선암 바이오마커 산업에는 주목할 만한 성장 기회가 존재합니다. 신규 바이오마커 패널의 발견과 검증을 목적으로 한 학계와 산업의 공동 연구가 활발해지고 있습니다. PSA의 한계에 대한 인식이 높아지고 가치 기반 치료에 대한 강조가 높아짐에 따라 보다 유익하고 덜 침습적인 진단으로 전환하려는 강력한 추진력이 있습니다.

이 부문이 계속 발전함에 따라 전립선암 진단학은 보다 통합적이고 개별화된 모델로 이동하고 있으며, 거기서 분자적인 통찰이 조기 발견뿐만 아니라 치료법의 결정과 장기적인 관리 전략을 도출하게 됩니다.

시장의 주요 참가 기업으로는 Exact Sciences, Myriad Genetics, Bio-Techne, Olympus Corporation, OPKO Health 등을 들 수 있습니다. Myriad Genetics의 Prolaris 검사는 전립선암 예후를 위한 '첨단 도구(Advanced Tool)'로서 미국 종합 암 네트워크(NCCN)의 인정을 계속 받고 있습니다.

전립선 암 바이오 마커 시장 보고서 하이라이트

  • 유형별로, 단백질 바이오마커는 2024년에 57.73%의 최대 판매 점유율을 차지했습니다. 멀티플렉스 분석과 4Kscore와 같은 위험 계층화 기술의 진보는 진단 정확도를 높이고 있습니다.
  • 스크리닝과 조기 발견은 시장을 독점했으며 2024년에는 45.14%의 최대 점유율을 차지했습니다.예를 들어, PSA 검사는 여전히 글로벌 표준으로 남아 있으며, PHI(전립선 건강 지수)와 4Kscore는 특이성을 개선하여 불필요한 생검을 줄입니다.
  • 병원과 진단 실험실은 환자의 진단, 생검 평가, 치료 계획에서 중심적인 역할을 담당하기 때문에 전립선암 바이오마커 산업의 주요 촉진요인이 되고 있습니다. 조기 발견 검사에 대한 수요가 시장 성장의 연료가 되고 있습니다. 또한, 일상적인 비뇨기과 워크플로우나 병원 베이스의 암 스크리닝 프로그램에 바이오마커 검사가 통합되는 것으로, 선진 지역과 신흥 지역의 양쪽 모두에 있어서의 검사의 채용과 개발이 한층 더 촉진됩니다.
  • 북미는 첨단 진단 역량, 정밀 의학의 빠른 도입, 그리고 이를 뒷받침하는 규제 프레임워크 덕분에 전립선암 바이오마커 시장을 선도하고 있습니다. ExoDx Prostate (Bio-Techne의 소변 기반 엑소좀 RNA 검사) 및 SelectMDx (MDxHealth의 mRNA 검사)와 같은 바이오마커 기반 검사들은 조직 검사(biopsy) 결정에 널리 활용되고 있습니다. Network(NCCN)의 임상 가이드라인은 바이오마커의 사용을 권장하고 있습니다.
  • 아시아태평양은 2025-2030년까지의 예측기간에서 CAGR 14.4%로 가장 빠른 성장을 이룰 것으로 예측됩니다. 이것은 중국, 인도, 일본 등의 국가에서 암에 대한 의식이 높아지고, 헬스케어 인프라 개선, 헬스케어 지출 증가로 인한 것입니다. PSA 스크리닝 및 PHI 및 4Kscore와 같은 최신 테스트에 대한 접근성이 확대됨에 따라 조기 발견이 촉진되고 있습니다. 지방자치단체는 전국적인 암 검진 이니셔티브를 시작하고 있어 정밀의료나 분자진단에 대한 투자의 확대가 바이오마커의 채택을 뒷받침하고 있습니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 전립선암 바이오마커 시장의 변수, 동향, 범위

  • 전립선암 바이오마커 시장의 계통 전망
    • 상위 시장 전망
  • 침투와 성장의 전망 매핑
  • 파이프라인 분석
    • 스크리닝과 조기 발견
    • 진단과 위험층별화
    • 예후와 치료 모니터링
    • 동반진단
  • 시장 역학
    • 시장 성장 촉진요인 분석
    • 시장 성장 억제요인 분석
  • 전립선암 바이오마커: 시장 분석 도구
    • 산업 분석 - Porter's Five Forces 분석
    • PESTLE 분석

제4장 전립선암 바이오마커 시장 : 부문 분석, 유형별, 2018-2030년

  • 전립선암 바이오마커 시장 : 유형 변동 분석

제5장 전립선암 바이오마커 시장 : 부문 분석, 용도별, 2018-2030년

  • 전립선암 바이오마커 시장 : 용도 변동 분석

제6장 전립선암 바이오마커 시장 : 부문 분석, 최종 용도별, 2018-2030년

  • 전립선암 바이오마커 시장 : 최종 용도 변동 분석

제7장 전립선암 바이오마커 시장 : 지역별 부문 분석, 2018-2030년

  • 지역 시장 현황
  • 북미
  • 유럽
  • 아시아태평양
  • 라틴아메리카
  • 중동 및 아프리카

제8장 전립선암 바이오마커 시장 : 경쟁 분석

  • 기업 분류
  • 전략 매핑
    • 신제품 발매
    • 파트너십
    • 취득
    • 콜라보레이션
    • 자금조달
  • 2022년 기업의 시장 점유율 분석
  • 기업 프로파일
    • EXACT SCIENCES CORPORATION
    • MYRIAD GENETICS, INC.
    • BIO-TECHNE
    • EXODX
    • OPKO HEALTH,INC.
    • MDXHEALTH
    • VERACYTE, INC.
    • BECKMAN COULTER, INC.
    • NUCLEIX
    • DIACARTA
SHW 25.05.29

Prostate Cancer Biomarkers Market Growth & Trends:

The global prostate cancer biomarkers market size is expected to reach USD 9.8 billion by 2030, registering a CAGR of 13.1% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market is undergoing rapid evolution driven by the increasing demand for precision diagnostics and the limitations of conventional screening methods like PSA testing. PSA, while widely used, has low specificity, often leading to overdiagnosis and overtreatment. As a result, there is a significant shift towards molecular and genomic biomarkers that can offer improved diagnostic accuracy and guide clinical decisions. Emerging biomarkers such as PCA3 (Prostate Cancer Antigen 3), 4Kscore, and ConfirmMDx have demonstrated superior performance in risk stratification and biopsy decision support. These tests are increasingly being integrated into clinical practice to reduce unnecessary biopsies and improve patient outcomes.

A key market driver is the growing focus on personalized medicine. Genomic classifiers like Decipher and Oncotype DX GPS help determine the aggressiveness of prostate tumors and inform treatment planning, especially in early-stage patients deciding between active surveillance and intervention. Liquid biopsy-based technologies are also gaining attention for their non-invasive nature, with urine-based tests like SelectMDx and ExoDx offering clinically actionable insights for patients with elevated PSA. These innovations are particularly relevant in cases where traditional biopsies carry risks or yield inconclusive results.

Technological advancements in next-generation sequencing (NGS) and transcriptomics are further accelerating biomarker discovery. For example, studies have identified gene fusions such as TMPRSS2-ERG and mutations in BRCA1/2 and ATM as significant markers for prognosis and therapeutic guidance. The increasing use of these biomarkers in selecting patients for targeted therapies like PARP inhibitors reflects the rising importance of companion diagnostics in the treatment ecosystem. Moreover, metabolomic biomarkers, which analyze small-molecule metabolic changes associated with tumor progression, are emerging as promising tools for early detection and monitoring.

However, the market still faces several challenges. Standardization across biomarker assays remains limited, and there is a lack of consensus among clinicians regarding which tests to adopt and at what clinical stages. Reimbursement issues and cost concerns can hinder the routine use of advanced biomarker tests, particularly in regions with constrained healthcare budgets. Furthermore, regulatory pathways for biomarker approval are often lengthy, which can delay commercial availability. Even as newer tests enter the market, widespread clinical adoption requires large-scale validation studies and integration into existing clinical workflows.

Despite these barriers, the prostate cancer biomarker industry presents notable growth opportunities. Collaborations between academia and industry are intensifying, aimed at discovering and validating novel biomarker panels. With increasing awareness of the limitations of PSA and growing emphasis on value-based care, there is strong momentum to shift toward more informative, less invasive diagnostics. In this context, biomarkers like AR-V7, used for monitoring treatment resistance in advanced prostate cancer, illustrate the potential of biomarker-guided therapy selection.

As the field continues to advance, prostate cancer diagnostics are moving toward a more integrated and individualized model, where molecular insights guide not only early detection but also therapeutic decisions and long-term management strategies.

Some of the key players in the market are Exact Sciences, Myriad Genetics, Bio-Techne, Olympus Corporation, OPKO Health. These players are involved in various strategic initiatives such as product launch and approval in order to cater to a global clientele. For instance, in December 2024, Myriad Genetics' Prolaris test continues to be recognized by the National Comprehensive Cancer Network (NCCN) as an Advanced Tool for prostate cancer prognosis. It remains included in the NCCN guidelines with a Category 2A evidence level, indicating strong support (>=85%) from the NCCN prostate panel. This classification reinforces Prolaris' clinical relevance in helping guide treatment decisions based on tumor aggressiveness.

Prostate Cancer Biomarker Market Report Highlights:

  • Based on type, protein biomarkersaccounted for largest revenue share of 57.73% in 2024. The protein biomarkers segment in the prostate cancer biomarkers market is driven by the widespread clinical use of PSA and PHI tests, rising prostate cancer prevalence, and strong clinical guideline support. Technological advances in multiplex assays and risk stratification tools like the 4Kscore enhance diagnostic accuracy. Additionally, increased demand for non-invasive, cost-effective, and point-of-care testing solutions fuels further growth in this segment across both developed and emerging markets.
  • Based on application screening and early detection dominated the market and accounted for the largest share of 45.14% in 2024.The screening and early detection segment in the market is driven by rising disease prevalence, aging populations, and adoption of non-invasive tests. For example, PSA testing remains a global standard, while PHI (Prostate Health Index) and the 4Kscore offer improved specificity, reducing unnecessary biopsies. Programs like the U.S. Preventive Services Task Force (USPSTF) recommendation for PSA testing in men aged 55-69 further boost demand. Increased public awareness and improved access to diagnostic services also support growth in this segment.
  • Based on end use, hospitals and diagnostic laboratories segment dominated the market and accounted for the largest share of 63.24% in 2024.Hospitals and diagnostic laboratories are key drivers in the prostate cancer biomarker industry due to their central role in patient diagnosis, biopsy evaluation, and treatment planning. Increasing patient volumes, availability of advanced diagnostic infrastructure, and demand for accurate, early-stage detection tests like PSA, PHI, and ConfirmMDx fuel market growth. Additionally, integration of biomarker testing into routine urology workflows and hospital-based cancer screening programs further enhances test adoption and market expansion in both developed and emerging regions.
  • North America dominates the prostate cancer biomarkers market due to advanced diagnostic capabilities, early adoption of precision medicine, and supportive regulatory frameworks. Biomarker-based tests such as ExoDx Prostate (urine-based exosomal RNA test by Bio-Techne) and SelectMDx (mRNA test by MDxHealth) are widely utilized for biopsy decision-making. Additionally, clinical guidelines from the National Comprehensive Cancer Network (NCCN) endorse biomarker usage. Growing investment in genomics and partnerships between academic centers and biotech firms continue to drive innovation and biomarker adoption across the region.
  • Asia Pacific region is expected to witness fastest growth with a CAGR of 14.4% over the forecast period from 2025 to 2030, due to increasing cancer awareness, improving healthcare infrastructure, and rising healthcare expenditure in countries like China, India, and Japan. Expanding access to PSA screening and newer tests such as PHI and 4Kscore is driving early detection. Local governments are launching national cancer screening initiatives, and growing investments in precision medicine and molecular diagnostics are boosting biomarker adoption. Collaborations between regional hospitals and biotech firms are further fueling innovation and market expansion.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market Segmentation and Scope
    • 1.1.1 Segment Definition
      • 1.1.1.1 Application Segment
      • 1.1.1.2 Type Segment
      • 1.1.1.3 End Use Segment
  • 1.2 Regional Scope
  • 1.3 Estimates and Forecast Timeline
  • 1.4 Objectives
    • 1.4.1 Objective - 1
    • 1.4.2 Objective - 2
    • 1.4.3 Objective - 3
  • 1.5 Research Methodology
  • 1.6 Information Procurement
    • 1.6.1 Purchased Database
    • 1.6.2 Gvr's Internal Database
    • 1.6.3 Secondary Sources
    • 1.6.4 Primary Research
  • 1.7 Information or Data Analysis
    • 1.7.1 Data Analysis Models
  • 1.8 Market Formulation & Validation
  • 1.9 Model Details
    • 1.9.1 Commodity Flow Analysis
  • 1.10 List of Secondary Sources
  • 1.11 List of Abbreviations

Chapter 2 Executive Summary

  • 2.1 Market Outlook
  • 2.2 Application and Type Snapshot
  • 2.3 End Use Snapshot
  • 2.4 Competitive Landscape Snapshot

Chapter 3 Prostate Cancer Biomarkers Market Variables, Trends, and Scope

  • 3.1 Prostate Cancer Biomarkers Market Lineage Outlook
    • 3.1.1 Parent Market Outlook
  • 3.2 Penetration and Growth Prospect Mapping
  • 3.3 Pipeline Analysis
    • 3.3.1 Screening And Early Detection
    • 3.3.2 Diagnosis And Risk Stratification
    • 3.3.3 Prognosis And Treatment Monitoring
    • 3.3.4 Companion Diagnostics
  • 3.4 Market Dynamics
    • 3.4.1 Market Driver Analysis
      • 3.4.1.1 Rising prevalence of prostate cancer
      • 3.4.1.2 Advancements in Genomic and Proteomic Technologies
      • 3.4.1.3 Supportive Government and Research Initiatives
    • 3.4.2 Market Restraint Analysis
      • 3.4.2.1 High Cost of Biomarker-Based Tests
      • 3.4.2.2 Uneven Access to Advanced Diagnostic Infrastructure
  • 3.5 Prostate Cancer Biomarkers: Market Analysis Tools
    • 3.5.1 Industry Analysis - Porter's
    • 3.5.2 Pestle Analysis

Chapter 4 Prostate Cancer Biomarkers Market: Segment Analysis, By Type, 2018 - 2030 (USD Million)

  • 4.1 Prostate Cancer Biomarkers Market: Type Movement Analysis
    • 4.1.1 Genetic Biomarkers
      • 4.1.1.1 Genetic Biomarkers Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
    • 4.1.2 Protein Biomarkers
      • 4.1.2.1 Protein Biomarkers Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
    • 4.1.3 Cell-Based Biomarkers
      • 4.1.3.1 Cell-Based Biomarkers Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
    • 4.1.5 Metabolomic Biomarkers
      • 4.1.5.1 Metabolomic Biomarkers Prostate Cancer Biomarkers Market, 2018 - 2030, USD Million

Chapter 5 Prostate Cancer Biomarkers Market: Segment Analysis, By Application, 2018 - 2030 (USD Million)

  • 5.1 Prostate Cancer Biomarkers Market: Application Movement Analysis
    • 5.1.1 Screening And Early Detection
      • 5.1.1.1 Screening And Early Detection Market, 2018 - 2030 (USD Million)
    • 5.1.2 Diagnosis And Risk Stratification
      • 5.1.2.1 Diagnosis And Risk Stratification Market, 2018 - 2030 (USD Million)
    • 5.1.3 Prognosis And Treatment Monitoring
    • 5.3.1 Prognosis And Treatment Monitoring Market, 2018 - 2030 (USD Million)
    • 5.1.4 Companion Diagnostics
      • 5.1.4.1 Companion Diagnostics Market, 2018 - 2030 (USD Million)

Chapter 6 Prostate Cancer Biomarkers Market: Segment Analysis, By End Use, 2018 - 2030 (USD Million)

  • 6.1 Prostate Cancer Biomarkers Market: End Use Movement Analysis
    • 6.1.1 Hospitals And Diagnostic Laboratories
      • 6.1.1.1 Hospitals And Diagnostic Laboratories Market, 2018 - 2030 (USD Million)
    • 6.1.2 Academic And Research Institutes
      • 6.1.2.1 Academic And Research Institutes Market, 2018 - 2030 (USD Million)
    • 6.1.3 Biopharmaceutical Companies
      • 6.1.3.1 Biopharmaceutical Companies Market, 2018 - 2030 (USD Million)

Chapter 7 Prostate Cancer Biomarkers Market: Segment Analysis, By Region, 2018 - 2030 (USD Million)

  • 7.1 Regional Market Snapshot
  • 7.2 North America
    • 7.2.1 North America Prostate Cancer Biomarkers Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 7.2.2 U.S.
      • 7.2.2.1 U.S. Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.2.2.2 Key Country Dynamics
      • 7.2.2.3 Regulatory Framework
      • 7.2.2.4 Reimbursement Scenario
    • 7.2.3 Canada
      • 7.2.3.1 Canada Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.2.3.2 Key Country Dynamics
      • 7.2.3.3 Regulatory Framework
      • 7.2.3.4 Reimbursement Scenario
    • 7.2.4 Mexico
      • 7.2.4.1 Mexico Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.2.4.2 Key Country Dynamics
      • 7.2.4.3 Regulatory Framework
      • 7.2.4.4 Reimbursement Scenario
  • 7.3 Europe
    • 7.3.1 Europe Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
    • 7.3.2 UK
      • 7.3.2.1 UK Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.3.2.2 Key Country Dynamics
      • 7.3.2.3 Regulatory Framework
      • 7.3.2.4 Reimbursement Scenario
    • 7.3.3 Germany
      • 7.3.3.1 Germany Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.3.3.2 Key Country Dynamics
      • 7.3.3.3 Regulatory Framework
      • 7.3.3.4 Reimbursement Scenario
    • 7.3.4 Spain
      • 7.3.4.1 Spain Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.3.4.2 Key Country Dynamics
      • 7.3.4.3 Regulatory Framework
      • 7.3.4.4 Reimbursement Scenario
    • 7.3.5 France
      • 7.3.5.1 France Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.3.5.2 Key Country Dynamics
      • 7.3.5.3 Regulatory Framework
      • 7.3.5.4 Reimbursement Scenario
    • 7.3.6 Italy
      • 7.3.6.1 Italy Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.3.6.2 Key Country Dynamics
      • 7.3.6.3 Regulatory Framework
      • 7.3.6.4 Reimbursement Scenario
    • 7.3.7 Denmark
      • 7.3.7.1 Denmark Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.3.7.2 Key Country Dynamics
      • 7.3.7.3 Regulatory Framework
      • 7.3.7.4 Reimbursement Scenario
    • 7.3.8 Sweden
      • 7.3.8.1 Sweden Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.3.8.2 Key Country Dynamics
      • 7.3.8.3 Regulatory Framework
      • 7.3.8.4 Reimbursement Scenario
    • 7.3.9 Norway
      • 7.3.9.1 Norway Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.3.9.2 Key Country Dynamics
      • 7.3.9.3 Regulatory Framework
      • 7.3.9.4 Reimbursement Scenario
  • 7.4 Asia Pacific
    • 7.4.1 Asia-Pacific Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
    • 7.4.2 Japan
      • 7.4.2.1 Japan Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.4.2.2 Key Country Dynamics
      • 7.4.2.3 Regulatory Framework
      • 7.4.2.4 Reimbursement Scenario
    • 7.4.3 China
      • 7.4.3.1 China Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.4.3.2 Key Country Dynamics
      • 7.4.3.3 Regulatory Framework
      • 7.4.3.4 Reimbursement Scenario
    • 7.4.4 India
      • 7.4.4.1 India Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.4.4.2 Key Country Dynamics
      • 7.4.4.3 Regulatory Framework
      • 7.4.4.4 Reimbursement Scenario
    • 7.4.5 South Korea
      • 7.4.5.1 South Korea Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.4.5.2 Key Country Dynamics
      • 7.4.5.3 Regulatory Framework
      • 7.4.5.4 Reimbursement Scenario
    • 7.4.6 Thailand
      • 7.4.6.1 Thailand Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.4.6.2 Key Country Dynamics
      • 7.4.6.3 Regulatory Framework
      • 7.4.6.4 Reimbursement Scenario
    • 7.4.7 Australia
      • 7.4.7.1 Australia Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.4.7.2 Key Country Dynamics
      • 7.4.7.3 Regulatory Framework
      • 7.4.7.4 Reimbursement Scenario
  • 7.5 Latin America
    • 7.5.1 Latin America Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
    • 7.5.2 Brazil
      • 7.5.2.1 Brazil Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.5.2.2 Key Country Dynamics
      • 7.5.2.3 Regulatory Framework
      • 7.5.2.4 Reimbursement Scenario
    • 7.5.3 Argentina
      • 7.5.3.1 Argentina Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.5.3.2 Key Country Dynamics
      • 7.5.3.3 Regulatory Framework
      • 7.5.2.4 Reimbursement Scenario
  • 7.6 MEA
    • 7.6.1 MEA Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
    • 7.6.2 South Africa
      • 7.6.2.1 South Africa Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.6.2.2 Key Country Dynamics
      • 7.6.2.3 Regulatory Framework
      • 7.6.2.4 Reimbursement Scenario
    • 7.6.3 Saudi Arabia
      • 7.6.3.1 Saudi Arabia Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.6.3.2 Key Country Dynamics
      • 7.6.3.3 Regulatory Framework
      • 7.6.3.4 Reimbursement Scenario
    • 7.6.4 UAE
      • 7.6.4.1 UAE Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.6.4.2 Key Country Dynamics
      • 7.6.4.3 Regulatory Framework
      • 7.6.2.4 Reimbursement Scenario
    • 7.6.5 Kuwait
      • 7.6.5.1 Kuwait Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.6.5.2 Key Country Dynamics
      • 7.6.5.3 Regulatory Framework
      • 7.6.5.4 Reimbursement Scenario

Chapter 8 Prostate Cancer Biomarkers Market: Competitive Analysis

  • 8.1 Company Categorization
  • 8.2 Strategy Mapping
    • 8.2.1 New product launch
    • 8.2.2 Partnerships
    • 8.2.3 Acquisition
    • 8.2.4 Collaboration
    • 8.2.5 Funding
  • 8.3 Company Market Share Analysis, 2022
  • 8.4 Company Profiles
    • 8.4.1 EXACT SCIENCES CORPORATION
      • 8.4.1.1 Company overview
      • 8.4.1.2 Financial performance
      • 8.4.1.3 Product benchmarking
      • 8.4.1.4 Strategic initiatives
    • 8.4.2 MYRIAD GENETICS, INC.
      • 8.4.2.1 Company overview
      • 8.4.2.2 Financial performance
      • 8.4.2.3 Product benchmarking
      • 8.4.2.4 Strategic initiatives
    • 8.4.3 BIO-TECHNE
      • 8.4.3.1 Company overview
      • 8.4.3.2 Financial performance
      • 8.4.3.3 Product benchmarking
      • 8.4.3.4 Strategic initiatives
    • 8.4.4 EXODX
      • 8.4.4.1 Company overview
      • 8.4.4.2 Product benchmarking
      • 8.4.4.3 Product benchmarking
      • 8.4.4.4 Strategic initiatives
    • 8.4.5 OPKO HEALTH,INC.
      • 8.4.5.1 Company overview
      • 8.4.5.2 Product benchmarking
      • 8.4.5.3 Strategic initiatives
    • 8.4.6 MDXHEALTH
      • 8.4.6.1 Company overview
      • 8.4.6.2 Financial performance
      • 8.4.6.3 Product benchmarking
      • 8.4.6.4 Strategic initiatives
    • 8.4.7 VERACYTE, INC.
      • 8.4.7.1 Company overview
      • 8.4.7.2 Financial performance
      • 8.4.7.3 Product benchmarking
      • 8.4.7.4 Strategic initiatives
    • 8.4.8 BECKMAN COULTER, INC.
      • 8.4.8.1 Company overview
      • 8.4.8.2 Product benchmarking
    • 8.4.9 NUCLEIX
      • 8.4.9.1 Company overview
      • 8.4.9.2 Financial performance
      • 8.4.9.3 Product benchmarking
      • 8.4.9.4 Strategic initiatives
    • 8.4.10 DIACARTA
      • 8.4.10.1 Company overview
      • 8.4.10.2 Product benchmarking
      • 8.4.10.3 Strategic initiatives
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제